The 59.21% Simple Moving Average of Solid Biosciences Inc’s (SLDB) Stock in the Past 200 Days

The stock of Solid Biosciences Inc (SLDB) has gone down by -13.13% for the week, with a -37.22% drop in the past month and a 23.30% rise in the past quarter. The volatility ratio for the week is 5.87%, and the volatility levels for the past 30 days are 8.25% for SLDB. The simple moving average for the past 20 days is -23.19% for SLDB’s stock, with a 59.21% simple moving average for the past 200 days.

Is It Worth Investing in Solid Biosciences Inc (NASDAQ: SLDB) Right Now?

The 36-month beta value for SLDB is at 1.99. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 as “hold,” and 1 as “sell.”

The public float for SLDB is 30.25M, and currently, shorts hold a 3.04% of that float. The average trading volume for SLDB on April 19, 2024 was 270.17K shares.

SLDB) stock’s latest price update

The stock price of Solid Biosciences Inc (NASDAQ: SLDB) has dropped by -7.31 compared to previous close of 9.99. Despite this, the company has seen a fall of -13.13% in its stock price over the last five trading days. Seeking Alpha reported 2024-04-10 that Solid Biosciences is focused on gene therapy innovation for neuromuscular and cardiac conditions. Their flagship drug therapy for Duchenne muscular dystrophy (DMD) is expected to be tested in Q2 2024. SLDB recently received additional liquidity from a PIPE investment, improving its risk-reward equation.

Analysts’ Opinion of SLDB

Many brokerage firms have already submitted their reports for SLDB stocks, with William Blair repeating the rating for SLDB by listing it as a “Outperform.” The predicted price for SLDB in the upcoming period, according to William Blair is $40 based on the research report published on March 28, 2024 of the current year 2024.

Citigroup, on the other hand, stated in their research note that they expect to see SLDB reach a price target of $16. The rating they have provided for SLDB stocks is “Buy” according to the report published on March 15th, 2024.

Piper Sandler gave a rating of “Overweight” to SLDB, setting the target price at $20 in the report published on March 14th of the current year.

SLDB Trading at -14.57% from the 50-Day Moving Average

After a stumble in the market that brought SLDB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.47% of loss for the given period.

Volatility was left at 8.25%, however, over the last 30 days, the volatility rate increased by 5.87%, as shares sank -30.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +24.63% upper at present.

During the last 5 trading sessions, SLDB fell by -13.13%, which changed the moving average for the period of 200-days by +77.39% in comparison to the 20-day moving average, which settled at $11.85. In addition, Solid Biosciences Inc saw 50.81% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at SLDB starting from Ganot Ilan, who sale 139 shares at the price of $7.99 back on Jan 29 ’24. After this action, Ganot Ilan now owns 8,416 shares of Solid Biosciences Inc, valued at $1,111 using the latest closing price.

PERCEPTIVE ADVISORS LLC, the Director of Solid Biosciences Inc, purchase 3,410,713 shares at $5.53 during a trade that took place back on Jan 11 ’24, which means that PERCEPTIVE ADVISORS LLC is holding 6,833,539 shares at $18,861,243 based on the most recent closing price.

Stock Fundamentals for SLDB

The total capital return value is set at -0.69. Equity return is now at value -56.79, with -45.16 for asset returns.

Based on Solid Biosciences Inc (SLDB), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -3.59. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is 53.19.

Currently, EBITDA for the company is -101.73 million with net debt to EBITDA at 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.94.


In conclusion, Solid Biosciences Inc (SLDB) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts